Trial reportEuropean journal of medical research2025
Vibrating mesh nebulizers vs. less invasive surfactant administration in the treatment of preterm respiratory distress syndrome: a multicenter, open-label, exploratory, randomized clinical trial.
Trial report in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Vibrating Mesh Nebulizer (A-VMN) Performance During Low-Flow Nasal Oxygen Therapy in Neonates.Pharmaceutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
objectiveDeficiency of pulmonary surfactant (PS) induces the onset of neonatal respiratory distress syndrome (RDS), which can lead to progressively worsening respiratory failure and even death. However, studies on improving lung function via the use of vibrating mesh nebulizer (VMN) technology to deliver PS to premature infants with RDS are limited.
methodsThis prospective multicenter, open-label, exploratory, randomized clinical trial, including 2 parallel groups and a 1:1 allocation, was conducted in 7 hospitals from Jan. 1, 2023, to Dec. 31, 2024. Premature infants born at less than 32 weeks of gestation and weighing less than 1500 g who presented after birth with RDS with the need for noninvasive ventilatory support as initial treatment were eligible for inclusion.
resultsOf the 49 eligible premature infants, 25 were randomized to the VMN group, and 24 to the less invasive surfactant administration (LISA) group. We did not find a difference in the need for mechanical ventilation via an endotracheal tube (MVET) within 72 h between the VMN and LISA groups (3 [12.00%] vs. 5 [20.80%]; odds ratio, 0.52; 95% confidence intervals (CI), 0.11-2.46; P = 0.653). Comparing the LISA group, the incidence of apnea of prematurity and transient decrease in oxygen saturation was lower in the VMN group (2[8.00%] vs. 10 [41.67%]; odds ratio [OR], 0.10; 95% CI 0.02-0.54, P = 0.003; 3[12.00%] vs. 16[66.67%]; OR, 0.10; 95% CI 0.02-0.30, P < 0.001). However, there was no difference in the bronchopulmonary dysplasia (BPD), death in hospital, pneumothorax, periventricular leukomalacia (PVL), retinopathy of prematurity (ROP), necrotizing enterocolitis (NEC), periventricular-intraventricular hemorrhage (PIVH), and application of PS again between the two groups (all P > 0.05).
conclusionIn this exploratory clinical trial, compared with LISA, the noninvasive VMN technique may be a safe and well-tolerated approach for PS delivery in preterm infants with RDS.
trial registrationChiCTR2300072262 ( https://www.chictr.org.cn )."
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.